Inflammatory markers and the risk of chronic obstructive pulmonary disease: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Su, Bin ^a,b   Liu, Tiansheng ^a   Fan, Haojun ^a   Chen, Feng ^a   Ding, Hui ^a   Wu, Zhouwei ^a   Wang, Hongwu ^b   Hou, Shike ^a  

^a MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE; META ANALYSIS; OBSERVATIONAL STUDY; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; BLOOD; CASE CONTROL STUDY;

BIOMARKERS; CASE-CONTROL STUDIES; HUMANS; INFLAMMATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84977636838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150586     Document Type: Review

References (42)

1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370: 765-773. PMID: 17765526
2. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med. 2002; 166: 1218-1224. PMID: 12403691
3. Connors AF Jr., Dawson NV, Thomas C, Harrell FE Jr., Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154: 959-967. PMID: 8887592
4. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21: 347-360. PMID: 12608452
5. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2: 367-370; discussion 371-362. PMID: 16267364
6. Bartlett YK, Sheeran P, Hawley MS. Effective behaviour change techniques in smoking cessation interventions for people with chronic obstructive pulmonary disease: a meta-analysis. Br J Health Psychol. 2014; 19: 181-203. doi: 10.1111/bjhp.12071 PMID: 24397814
7. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011; 11: 36. doi: 10. 1186/1471-2466-11-36 PMID: 21672193
8. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J. 2009; 34: 634-640. doi: 10. 1183/09031936.00167708 PMID: 19357145
9. Foschino Barbaro MP, Carpagnano GE, Spanevello A, Cagnazzo MG, Barnes PJ. Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol. 2007; 20: 753-763. PMID: 18179748
10. Liu X, Ji Y, Chen J, Li S, Luo F. Circulating visfatin in chronic obstructive pulmonary disease. Nutrition. 2009; 25: 373-378. doi: 10.1016/j.nut.2008.09.008 PMID: 19056239
11. Yasuda N, Gotoh K, Minatoguchi S, Asano K, Nishigaki K, Nomura M, et al. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Respir Med. 1998; 92: 993-999.PMID: 9893764
12. Wang XR, Li YP, Gao S, Xia W, Gao K, Kong QH, et al. Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014; 9: 543-549. doi: 10.2147/COPD.S62700 PMID: 24920892
13. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010; 11: 63. doi: 10.1186/1465-9921-11-63 PMID: 20500811
14. Aaron SD, Vandemheen KL, Ramsay T, Zhang C, Avnur Z, Nikolcheva T, et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir Res. 2010; 11: 41. doi: 10.1186/1465-9921-11-41 PMID: 20412595
15. Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab. 2009; 55: 31-40. PMID: 19350847
16. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, Rzeszutko M, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost. 2009; 102: 1176-1182. doi: 10.1160/TH09-02-0118 PMID: 19967149
17. Fattouh M, Alkady O. Inflammatory biomarkers in chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2014; 63: 799-804.
18. Harting JR, Gleason A, Romberger DJ, Von Essen SG, Qiu F, Alexis N, et al. Chronic obstructive pulmonary disease patients have greater systemic responsiveness to ex vivo stimulation with swine dust extract and its components versus healthy volunteers. J Toxicol Environ Health A. 2012; 75: 1456-1470. doi: 10.1080/15287394.2012.722186 PMID: 23116451
19. Van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GJ, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006; 38: 1543-1552. PMID: 16960513
20. Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med. 2008; 19: 104-108. doi: 10.1016/j.ejim.2007.04.026 PMID: 18249305
21. Petersen AM, Mittendorfer B, Magkos F, Iversen M, Pedersen BK. Physical activity counteracts increased whole-body protein breakdown in chronic obstructive pulmonary disease patients. Scand J Med Sci Sports. 2008; 18: 557-564. PMID: 18067517
22. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7: e37483. doi: 10.1371/journal.pone.0037483 PMID: 22624038
23. Barreiro E, Schols AM, Polkey MI, Galdiz JB, Gosker HR, Swallow EB, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax. 2008; 63: 100-107. PMID: 17875568
24. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59: 574-580. PMID: 15223864
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6: e1000097. doi: 10.1371/journal. pmed.1000097 PMID: 19621072
26. Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In Ottawa (ON): Ottawa Hospital Research Institute 2000.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
28. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005; 25: 646-654. PMID: 16282215
29. Tobias A. Assessing the influence of a single study in meta-analysis. Stata Tech Bull. 1999; 47: 15-17.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. PMID: 12958120
31. Deeks JJ, Higgins JPT, AD G. (2008) Chapter 9: analysing data and undertaking meta-analysis. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions version 501. Oxford, UK: The Cochrane Collaboration.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. PMID: 9310563
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101. PMID: 7786990
34. Bircan A, Gokirmak M, Kilic O, Ozturk O, Akkaya A. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract. 2008; 17: 202-208. doi: 10.1159/000117793 PMID: 18408388
35. He Z, Chen Y, Chen P, Wu G, Cai S. Local inflammation occurs before systemic inflammation in patients with COPD. Respirology. 2010; 15: 478-484. doi: 10.1111/j.1440-1843.2010.01709.x PMID: 20210891
36. Kersul AL, Iglesias A, Rios A, Noguera A, Forteza A, Serra E, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2011; 47: 176-183. doi: 10.1016/j.arbres.2010.12.003 PMID: 21454005
37. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003; 114: 758-762. PMID: 12829203
38. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61: 23-28. PMID: 16143583
39. Feng E, Wan R, Yang S, Yan Z, Wang S, He W, et al. Expression levels of induced sputum IL-8 and IL-10 and drug intervention effects in patients with acute exacerbated COPD complicated with chronic cor pulmonale at high altitude. Exp Ther Med. 2013; 6: 747-752. PMID: 24137259
40. Valvi D, Mannino DM, Mullerova H, Tal-Singer R. Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts. Int J Chron Obstruct Pulmon Dis. 2012; 7: 173-182. doi: 10.2147/COPD.S29892 PMID: 22419864
41. van den Borst B, Gosker HR, Wesseling G, de Jager W, Hellwig VA, Snepvangers FJ, et al. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. Am J Clin Nutr. 2011; 94: 1504-1512. doi: 10.3945/ajcn.111.023911 PMID: 22071714
42. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003; 97: 1299-1302. PMID: 14682411